Anti-GP119/ GPR119/ GPCR2 monoclonal antibody
Anti-GP119/ GPR119/ GPCR2 antibody for FACS & in-vivo assay
Go to GPR119/GPR119 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T93788-Ab-1/ GM-Tg-hg-T93788-Ab-2 | Anti-Human GPR119 monoclonal antibody | Human |
GM-Tg-rg-T93788-Ab-1/ GM-Tg-rg-T93788-Ab-2 | Anti-Rat GPR119 monoclonal antibody | Rat |
GM-Tg-mg-T93788-Ab-1/ GM-Tg-mg-T93788-Ab-2 | Anti-Mouse GPR119 monoclonal antibody | Mouse |
GM-Tg-cynog-T93788-Ab-1/ GM-Tg-cynog-T93788-Ab-2 | Anti-Cynomolgus/ Rhesus macaque GPR119 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T93788-Ab-1/ GM-Tg-felg-T93788-Ab-2 | Anti-Feline GPR119 monoclonal antibody | Feline |
GM-Tg-cang-T93788-Ab-1/ GM-Tg-cang-T93788-Ab-2 | Anti-Canine GPR119 monoclonal antibody | Canine |
GM-Tg-bovg-T93788-Ab-1/ GM-Tg-bovg-T93788-Ab-2 | Anti-Bovine GPR119 monoclonal antibody | Bovine |
GM-Tg-equg-T93788-Ab-1/ GM-Tg-equg-T93788-Ab-2 | Anti-Equine GPR119 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T93788-Ab-1/ GM-Tg-hg-T93788-Ab-2; GM-Tg-rg-T93788-Ab-1/ GM-Tg-rg-T93788-Ab-2; GM-Tg-mg-T93788-Ab-1/ GM-Tg-mg-T93788-Ab-2; GM-Tg-cynog-T93788-Ab-1/ GM-Tg-cynog-T93788-Ab-2; GM-Tg-felg-T93788-Ab-1/ GM-Tg-felg-T93788-Ab-2; GM-Tg-cang-T93788-Ab-1/ GM-Tg-cang-T93788-Ab-2; GM-Tg-bovg-T93788-Ab-1/ GM-Tg-bovg-T93788-Ab-2; GM-Tg-equg-T93788-Ab-1/ GM-Tg-equg-T93788-Ab-2 |
Products Name | Anti-GPR119 monoclonal antibody |
Format | mab |
Target Name | GPR119 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-GPR119 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species GP119/ GPR119/ GPCR2 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-T93788 |
Target Name | GPR119 |
Gene ID | 139760,236781,302813,703368,492134,101083248,524232,100054460 |
Gene Symbol and Synonyms | GPCR2,GPR119 |
Uniprot Accession | Q8TDV5,Q7TQN8 |
Uniprot Entry Name | GP119_HUMAN,GP119_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000147262 |
Target Classification | GPCR |
The target: GPR119, gene name: GPR119, also named as GPCR2. This gene encodes a member of the rhodopsin subfamily of G-protein-coupled receptors that is expressed in the pancreas and gastrointestinal tract. The encoded protein is activated by lipid amides including lysophosphatidylcholine and oleoylethanolamide and may be involved in glucose homeostasis. This protein is a potential drug target in the treatment of type 2 diabetes.[provided by RefSeq, Jan 2010].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.